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Abstract 
Background: Impairments in psychosocial functioning have been demonstrated in 30–60% of adults with bipolar 
disorder (BD). However, the majority of studies investigating the effect of comorbid mental health disorders and age 
at onset outcomes in BD have focused on traditional outcome measures such as mood symptoms, mortality and 
treatment response. Therefore, this project aimed to investigate the impact of comorbid mental health disorders and 
age at onset on longitudinal psychosocial outcome in participants with BD.
Method: Mixed effects modelling was conducted using data from the Stanley Foundation Bipolar Network. Baseline 
factors were entered into a model, with Global Assessment of Functioning (GAF) score as the longitudinal outcome 
measure. Relative model fits were calculated using Akaike’s Information Criterion.
Results: No individual comorbidities predicted lower GAF scores, however an interaction effect was demonstrated 
between attention deficit hyperactivity disorder (ADHD) and any anxiety disorder (t = 2.180, p = 0.030). Participants 
with BD I vs BD II (t = 2.023, p = 0.044) and those in the lowest vs. highest income class (t = 2.266, p = 0.024) predicted 
lower GAF scores. Age at onset (t = 1.672, p = 0.095) did not significantly predict GAF scores.
Conclusions: This is the first study to demonstrate the negative psychosocial effects of comorbid anxiety disorders 
and ADHD in BD. This study adds to the growing database suggesting that comorbid mental health disorders are a 
significant factor hindering psychosocial recovery.
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Background
Bipolar disorder (BD) is a mood disorder characterised by 
recurrent episodes of mania, hypomania, and depression, 
separated by periods of euthymia. Although not charac-
terised by mood symptoms, psychosocial functioning 
appears to remain impaired during euthymia (Marangell 
et al. 2009). Psychosocial functioning is an essential com-
ponent of a person’s quality of life (QoL), and includes 
social, psychological and occupational domains. In 2001, 
a landmark review found that between 30 and 60% of 
adults with BD had significant impairments in occupa-
tional and social functioning during periods of euthymia 
(MacQueen et al. 2001). A possible explanation for per-
vasive psychosocial dysfunction may be the illness itself 
or the high prevalence of comorbid mental disorders 
in BD (Post et al. 2015). However, research into BD has 
often overlooked the role of psychosocial functioning.
High rates of anxiety disorders (AnxD) comorbid with 
BD have been found consistently in both epidemiologi-
cal (Merikangas et al. 2011) and clinical (Otto et al. 2006) 
samples. A recent review of 25 studies concluded that the 
lifetime risk of developing a comorbid AnxD was 46.8%, 
although epidemiological samples put this figure closer 
to 70% (Vazquez et  al. 2014). Comorbid AnxD in sub-
jects with BD are associated with a more severe illness 
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course, including increased number of mood episodes, 
suicide attempts and hospitalizations, compared to BD 
alone (Merikangas et al. 2007). Despite this considerable 
evidence base, a recent review highlighted the current 
stagnation in AnxD comorbidity research, epitomised by 
the poor understanding of psychosocial factors, scarcity 
of treatment studies, and the lack of evidence base on 
antidepressants treating bipolar depression (Provencher 
et  al. 2012). Although studies have shown associations 
between comorbid AnxD and poor psychosocial func-
tioning (Scott et  al. 2014), the picture is still far from 
clear.
Comorbid substance use disorders (SUD) are also 
prevalent the BD population, with epidemiological sur-
veys putting lifetime prevalence of comorbid SUD at as 
high as 42.3% (Merikangas et al. 2007). However, with the 
exception of alcohol (Hobbs et  al. 2011), the functional 
impacts and treatment options for individual SUD in BD 
have yet to be rigorously investigated.
Attention deficit hyperactivity disorder (ADHD) is 
a neurodevelopmental disorder, and its prevalence in 
BD varies widely with the age at which it is estimated. 
Approximately 20% of adult patients with ADHD also 
have bipolar disorder, while 10–20% of patients with 
bipolar disorder have adult ADHD (Brus et al. 2014). As 
with SUD and AnxD, ADHD comorbidity has been asso-
ciated with increased number of mood episodes, higher 
rates of suicide attempts (McIntyre et al. 2010) and psy-
chosocial dysfunction (Sentissi et al. 2008).
Mental health comorbidities in BD are more likely to 
be multiple than singular, with the World Mental Health 
Survey reporting a 62% lifetime prevalence of 3 or more 
comorbidities when strict Diagnostic and Statistical 
Manual of Mental Disorders-IV (DSM-IV) criteria were 
applied (Merikangas et al. 2011). However, research into 
the psychosocial effects of multiple comorbidities in BD 
is limited, often due to lack of power in subgroup analy-
ses (Sentissi et al. 2008). Although there is clear evidence 
of increased rates of both individual and multiple comor-
bidities in BD, their impacts on day-to-day functioning of 
people with BD have yet to be established.
Earlier age at onset (AAO) of BD is consistently linked 
with poorer clinical outcomes, including rapid cycling, 
greater number of mood episodes and increased risk of 
suicide (Leverich et  al. 2007). Some studies have linked 
psychosocial dysfunction with younger (< 18 years) AAO 
(Perlis et  al. 2009), although this finding is not consist-
ent (Martinez-Aran et  al. 2007). The studies that have 
focused on younger AAO suggest that psychosocial 
impairment is due to earlier disruption in the develop-
ment of interpersonal skills needed to build and main-
tain healthy relationships as patients grow older (Levy 
and Manove 2012). However, while younger AAO is 
associated with an adverse course of illness in adulthood 
(Leverich et al. 2007), how these may be related to psy-
chosocial functioning has received little attention (Perlis 
et al. 2009).
In this post hoc analysis we used data from an estab-
lished database (Stanley Foundation Bipolar Network) 
(Post et al. 2001) to estimate the effects of comorbid men-
tal health disorders and AAO on psychosocial outcomes 
in participants with BD. A novel aspect to this study is 
the use of statistical modelling techniques, specifically 
mixed effects modelling (MEM). Modelling has been 
used extensively in the behavioural sciences (Gerhard 
et  al. 1995), while recognition of its utility in medical 
fields is growing. The STEP-BD group used MEM in two 
papers assessing psychosocial outcome measures (Otto 
et al. 2006; Perlis et al. 2009). Complex data sets, such as 
the SFBN, often violate the assumptions of general linear 
modelling; in particular, statistical assumptions relating 
to independence between observations are violated. In 
contrast, mixed effects modelling is particularly suited 
to data sets involving measurements obtained from indi-
vidual patients that share socioeconomic, demographic 
or biomedical characteristics. Therefore, a key advantage 
of MEM is that it calculates how much of the variance in 
the sample is explained by each factor and, crucially, what 
residual variance is left. Most clinical studies lack suffi-
cient numbers to run the more complex models, but the 
longitudinal nature and size of the SFBN cohort makes 
this a unique opportunity in psychiatric research.
Aims of the study
Psychosocial functioning is key to understanding the 
overall impact mental health disorders can have on an 
individual. In BD research, comorbid mental health dis-
orders and age at onset have both been extensively inves-
tigated with traditional outcome measures such as mood 
symptoms, mortality and treatment response. In this 
study, we used Mixed-Effects Modelling on data collected 
by the Stanley Foundation Bipolar Network. The study 
aimed to demonstrate the effect of comorbid mental 
health disorders and age of onset on psychosocial func-
tioning in participants with BD.
Methods
Baseline assessments
Information on comorbid mental health disorders and 
AAO was collected utilizing items from Structured Clini-
cal Interview for DSM-IV-Patient (SCID-P) and Patient 
Questionnaire (PQ). AAO was defined as age at first 
hypomanic, manic, or depressive symptoms that were 
associated with functional impairment. AAO for BD was 
collected from the SCID-P, which a previous SFBN paper 
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showed to be highly correlated with self-report from PQ 
(r = 0.80) (Leverich et al. 2007).
Longitudinal outcome
The Global Assessment of Functioning (GAF) is a well-
validated instrument, which constitutes Axis V of DSM-
IV. It has been used extensively in BD research and has 
good inter-rater reliability (Jones et al. 1995). A criticism 
of the GAF is that it confounds mood and functioning by 
including mood symptoms in the scale descriptions. In 
the SFBN this was addressed by ensuring clinicians only 
used the GAF to rate functioning. Following an interview, 
clinicians rated the participant’s global functioning on a 
scale of 0–100. Three scores were recorded: best, worst 
(since last visit) and current. This study only included 
current score in order not to introduce a selection bias.
Data selection
The total sample study size in the original data was 
n = 648, with 21,993 GAF records. Only participants with 
complete data were included (see Fig. 1) which left a final 
sample size of n = 469, with 12,556 GAF records.
Data analysis
Mixed-effects models (MEMs) were developed using the 
strategy described by Pinheiro et  al. (2017) to examine 
variation in psychosocial dysfunction among partici-
pants at follow-up. A GAF score for each participant was 
obtained at baseline and at follow-up. We implemented 
the methodology proposed by Vickers and Altman (2001) 
and used GAF at baseline in order to control for differ-
ences in the mean psychosocial function between sites 
in Europe (Netherlands and Germany) and USA. The 
impact of BD subtype of each participant, AAO and the 
mental health comorbidities on psychosocial outcome 
were also determined. The influences of demographic 
characteristics of participants were assessed by includ-
ing sex and income as independent explanatory variables. 
Independent explanatory variables were assessed within 
models additively. The potential impact of multiple inter-
actions between AnxD, SUD and ADHD on psychosocial 
outcome was also explored. Individuals were grouped 
according to their respective locations (Europe or USA). 
Study location was then specified as a random-effect 
within the model in order to capture potential sources of 
unmeasured variation in psychosocial outcome. In addi-
tion, GAF at baseline within the random-effects structure 
was incorporated to generate a random intercept and 
random slope model that controlled for variation in over-
all mean and gradient between locations. Multi-model 
inference (Burnham and Anderson 2002) was used to 
compare models with additive terms to those models that 
incorporated both additive and interaction actions terms. 
A model with the lowest Akaike’s Information Criterion 
(AIC) (Akaike 1973) was considered to be the model that 
best described variation within data.
Results
Preliminary analysis
There were greater numbers of participants included in 
the final analysis from USA (n = 332) than from Europe 
(n = 137). However, a Chi-squared test of independ-
ence did not find differences in the distribution of gen-
ders between USA (female:male, 189:124) and Europe 
(female:male, 70:63) (Χ2 = 2.17, p = 0.141). In contrast, 
the distribution of mental health comorbidities, namely 
Total records 
(21,993)
No naturalisc 
follow-up 
(20,048)
Missing PQ or 
SCID-P (17,177)
Duplicate records 
(16,824)
Other missing 
data* (12,556)
Fig. 1 Flow-chart of exclusion criteria (GAF record number) *No GAF 
score/inadequate information, no gender, no income, no education, 
no age at first treatment for mania, no BD type, no AAO, negative 
duration of untreated bipolar
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AnxD (Χ2 = 22.98, p = < 0.001), ADHD (Χ2 = 8.23, 
p = 0.004) and SUD (Χ2 = 20.29, p < 0.001) all differed 
significantly between locations, and were higher in 
the US than in Europe. No significant differences in 
the distribution of BD subtypes (Χ2 = 0.44, p = 0.081), 
or income classes (Χ2 = 0.58, p = 0.748) was observed 
between USA and Europe. Demographic information 
for the whole sample is given in Table 1, while clinical 
and GAF summaries are given in Table 2.
Preliminary analysis undertaken using a Wilcoxon 
Signed-Rank Test indicated that the location of mean 
of GAF measured at baseline was significantly differ-
ent between locations (W = 23,472, p = 0.0325), and 
higher in Europe. The location of the mean GAF derived 
at follow-up was also found to be significantly different 
between locations (W = 24,844, p = 0.0012). It was not 
possible to explore the impact of educational attainment 
in the assessment of variation in GAF due to imbalance 
in sample size between the lower and higher levels of 
attainment. Similarly, participants with BD NOS were 
removed from further analyses due to insufficient sample 
size (n = 9). Subsequently, variation in psychosocial func-
tion among 446 participants was analysed.
Statistical analysis of global assessment of functioning 
(GAF)
The relative fits of MEMs were compared using multi-
model inference. A model was considered a plausible fit 
to data if the difference in AIC between models did not 
exceed ∆I < 2 (Table 3). The model incorporating an inter-
action between AnxD and ADHD was considered to be 
the best candidate model from the specific set of mod-
els compared (AIC = 3582.256, ∆I = 0.000) (Table 3). The 
model incorporating comorbidities additively was ranked 
second within the model set (AIC = 3588.113, ∆I = 5.361) 
and models that examined interactions between ADHD 
and SUD (AIC = 3593.008, ∆I = 10.256) and Anxiety 
Disorders and SUD (AIC = 3594.422, ∆I = 11.670) were 
ranked third and fourth, respectively.
Results generated by MEMs examining variation in 
GAF scores at follow-up, and incorporating an interac-
tion between AnxD and ADHD are presented in Table 4. 
Table 1 Demographic characteristics and  comorbidity 
in USA vs Europe
USA 
(n = 332, 
70.8%)
Europe 
(n = 137, 
29.2%)
Total 
(n = 469, 
100%)
χ2 p-value
Gender
 Female 59.9 52.6 57.8
 Male 40.1 47.4 42.2 2.17 0.141
Income ($)
 < 20,000 38.9 36.5 38.2
 20,000–59,999 38.6 42.3 39.7
 > 60,000 22.6 21.2 22.2 0.58 0.748
BD type
 BD I 84.3 83.2 84.0
 BD II 13.6 15.3 14.1
 BD cyclo-
thymic
2.1 1.5 1.9 0.44 0.081
Comorbidity
 AnxD 52.7 28.5 45.6 22.98 < 0.001
 Panic disorder 35.8 19.7 31.1
 Chronic AnxD 33.4 16.8 28.6
 OCD 22.9 4.4 17.5
 ADHD 16.6 6.6 13.6 8.23 0.004
 SUD 47.3 24.8 40.5 20.29 < 0.001
 AnxD + SUD 26.2 9.5 19.2
 ADHD + SUD 9.9 2.9 7.9
 ADHD + AnxD 13.3 5.8 11.1
Table 2 Sample demographics, mean GAF at baseline, and follow-up by location, sex and BD subtype
Location Sex DSM-IV bipolar 
disorder subtype
Mean follow-up 
attendance (%)
Mean GAF 
baseline
Mean GAF 
follow-up
Sample size (%)
Europe Female BD I 30.53 63.75 66.68 57 (12.5)
Europe Female BD II 40.85 73.08 71.62 13 (2.9)
Europe Female BD NOS 41.00 70.00 32.50 2 (0.40)
Europe Male BD I 31.04 64.16 71.02 56 (12.3)
Europe Male BD II 38.86 67.57 80 7 (1.5)
Europe Male BD NOS NA NA NA NA
USA Female BD I 24.22 62.84 65.25 165 (36.3)
USA Female BD II 24.08 64.33 68.46 24 (5.3)
USA Female BD NOS 11.75 54.00 62.75 4 (0.9)
USA Male BD I 28.47 61.02 65.03 104 (22.9)
USA Male BD II 26.50 63.20 67.70 20 (4.4)
USA Male BD NOS 42.33 71.00 61.00 3 (0.7)
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The global mean (Intercept) GAF at follow-up for par-
ticipants with BDI (reference level) was 67.757 and was 
significantly different from zero (t = 25.456, p ≤ 0.000). 
Participants with BDII were found to have significantly 
higher GAF scores at follow-up in comparison to partici-
pants with BDI (t = 2.023, p = 0.044). Baseline GAF for 
participants was found to be significantly and positively 
associated with GAF at follow-up (t = 3.586, = p ≤ 0.000). 
In addition, a significant negative association was found 
for participants with BDII and psychosocial function at 
baseline (t = − 2.059180, p = 0.017), suggesting lower 
psychosocial functioning in BDII patients at baseline. In 
contrast, there was no significant relationship between 
BD subtype and AAO and psychosocial function at fol-
low-up. Individuals grouped within the highest income 
class were significantly associated with higher GAF at 
follow-up in comparison to participants in the low-
est class (t = 2.266, p = 0.024). In contrast, there was no 
significant difference at follow-up between participants 
within income class-1 and income class-2. Comorbidi-
ties included as additive terms within the model, AnxD, 
SUD and ADHD, did not significantly affect psychosocial 
function at follow-up. However, when AnxD and ADHD 
were incorporated as an interaction term, a significant 
negative effect on GAF at follow-up was observed 
(t = 2.180, p = 0.030). The mean GAF at follow-up was 
not significantly affected by variation in duration of fol-
low-up, and no significant differences were observed in 
GAF score at follow-up between females and males.
Discussion
The aim of this study was to investigate the impact of 
comorbid mental disorders and AAO on psychosocial 
functioning in an international sample of participants 
with BD. These factors were entered into MEM with GAF 
score as the longitudinal psychosocial outcome measure. 
The principle finding is that BD comorbid with ADHD 
and AnxD predicted lower GAF scores, particularly in 
BDI. Due to the influence of confounding collinearity 
between explanatory variables, it was not possible to con-
struct a single model that examined the multiplicative 
effects between all comorbidities simultaneously. Never-
theless, a set of MEMs were developed that first exam-
ined the effects of comorbidities additively, in addition to 
models that examined the multiplicative effects between 
comorbidities independently. Individual comorbidities 
were explored independently within the final model, with 
Table 3 Multi-model inference indicating that the model incorporating two interactions terms best describes the data
Fixed effects structure (comorbidities) df Log likelihood AIC ∆i wt
Anxiety disorders and ADHD 24 − 1762.376 3582.752 0.000 0.928
Additive terms 25 − 1769.056 3588.113 5.361 0.064
ADHD and substance use disorder 23 − 1773.504 3593.008 10.256 0.006
Anxiety disorder and substance use disorder 27 − 1770.211 3594.422 11.670 0.003
Table 4 Mean GAF score at follow-up (intercept) and change with respect to explanatory variables
a Income-2: 20,000–59,999 (USD), income-3: > 60,000 (USD)
Parameter Estimate 95% CI se df t-value p-value
Intercept 67.757 62.225, 73.518 2.662 431 25.456 ≤ 0.000
BD: subtype-2 3.191 0.146, 0.645 1.578 431 2.023 0.044
Clinical follow-up attendance − 0.008 0.407, 6.908 0.029 431 − 0.287 0.774
GAF baseline 0.410 0.019, 0.308 0.114 431 3.586 ≤ 0.000
Age of onset 0.120 − 4.657, 2.122 0.072 431 1.672 0.095
Anxiety disorder − 2.162 − 4.823, 0.498 1.354 431 − 1.597 0.111
ADHD 1.279 − 2.979, 5.537 2.166 431 0.591 0.555
Substance use disorder 1.552 − 0.869, 3.973 1.232 431 1.260 0.208
Sex: male 0.771 − 1.650, 3.192 1.232 431 0.626 0.532
Income-2a − 0.551 − 3.261, 2.160 1.379 431 − 0.399 0.690
Income-3a 3.572 0.474, 6.670 1.576 431 2.266 0.024
BD subtype-2: GAF baseline − 0.265 − 0.518, − 0.012 0.129 431 − 2.059 0.040
BD subtype-2: age of onset − 0.244 − 0.518, − 0.029 0.139 431 − 1.758 0.080
Anxiety disorder: ADHD − 6.953 − 13.222,− 0.683 3.190 431 − 2.180 0.030
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no single comorbidity reaching statistical significance in 
predicting psychosocial outcome.
The high rate of comorbid AnxD in BD (45.6%) dem-
onstrated in this study is a well-replicated finding (Simon 
et al. 2004). BD and comorbid AnxD alone did not pre-
dict poorer psychosocial function in the present study. 
This adds to a limited evidence base, and warrants fur-
ther investigation. One explanation for this finding could 
be that the diagnostic criteria used did not capture the 
full spectrum of anxiety states and their effects.
As discussed earlier, rates of comorbid ADHD and BD 
vary widely according to age group. In the current study 
comorbid ADHD (13.6%) was less prevalent than both 
AnxD (45.6%) and SUD (40.5%). Currently, only two 
previous papers have looked at psychosocial outcome 
in comorbid ADHD and BD (Sentissi et al. 2008; Wilens 
et al. 2003). A study using more specific social function-
ing measures (SF-36 Health Survey and Social Adjust-
ment Scale) found that poorer scores were predicted 
by ADHD comorbidity (Sentissi et  al. 2008). Another 
smaller study found only a trend towards poorer global 
psychosocial functioning (GAF) in the ADHD group 
(Wilens et  al. 2003). Alongside the current results, this 
may suggest a specific social dysfunction related to 
ADHD comorbidity, since both studies also found that 
attention domains were significantly more impaired than 
hyperactivity domains in the comorbid ADHD group 
(Sentissi et  al. 2008; Wilens et  al. 2003). The evidence 
regarding specific attention deficits and social dysfunc-
tion needs further replication, however, it may be that the 
relationship between ADHD and BD depends upon to 
specific aspects of attention that are affected.
The current study did not find a predictive effect of 
comorbid SUD on psychosocial dysfunction in BD. It 
may have been an over-simplification to analyse all types 
of SUD together in this study. Alcohol and cannabis were 
the most widely abused substances in the SFBN sample, 
but a recent review highlighted the differential impacts 
of these two SUDs in BD (Cerullo and Strakowski 2007). 
The current results are especially interesting when look-
ing at the new DSM-5 (American Psychiatric Associa-
tion 2013) criteria for SUD, which no longer differentiate 
between substance abuse and dependence. Instead, SUD 
severity is classified by the number of criteria met. Of the 
11 criteria listed three relate to social impairment, mak-
ing it possible to have a SUD diagnosis without exhibiting 
any social dysfunction.
To the authors’ knowledge, this is the first paper that 
examines the effect of comorbid ADHD and AnxD on 
psychosocial outcome in BD. A key similarity between 
comorbid ADHD and AnxD individually with BD is 
the persistence of their symptoms during periods of 
euthymia (Bernardi et  al. 2010). This is likely to hinder 
psychosocial recovery between mood episodes, leading 
to reduced quality of life. The chronic nature of comor-
bid ADHD can lead to underreporting the functional 
impact of symptoms, (Sandra Kooij et al. 2008) although 
this has yet to be demonstrated in comorbid AnxD. We 
found that participants within the SFBN cohort with 
AnxD were significantly more likely to also have ADHD 
(OR = 5.821, 95% CI 3.00–12.233). This suggests a heavy 
burden of ADHD in those participants with comorbid 
AnxD and BD. While the detrimental influence of such a 
potent combination of mental health disorders is perhaps 
not surprising, the underlying pathophysiological mecha-
nisms merit further investigation.
The implications for treatment also merit discussion. 
There is very sparse guidance on treatment of comorbid 
mental health disorders in BD. The UK National Institute 
for Health and Care Excellence (NICE) guidelines merely 
state that clinicians should be “alert to the potential for 
drug interactions and use clinical judgement” (National 
Collaborating Centre for Mental Health 2014). Ameri-
can Psychiatric Association guidelines state treatment 
for comorbid AnxD and BD should “proceed concur-
rently” (American Psychiatric Association 2002). Cana-
dian/ISBD guidelines state that when ADHD is comorbid 
with mood disorders then the condition causing most 
impairment should be treated first (Bond et  al. 2012). 
This scenario can pose challenges for clinicians, as all 
three conditions are likely to be interacting to worsen the 
course of the other. In comorbid BD and ADHD, there is 
evidence in both children and adults to suggest a mood 
stabiliser and stimulant are effective in treating their 
respective symptoms (Findling et  al. 2007). However, 
in adults there is also evidence of stimulant associated 
(hypo)mania (Wingo and Ghaemi 2008). On the other 
hand, one could also consider psychological treatment 
for the comorbid ADHD such as CBT or skills’ training, 
which is not likely to harm treatment of BD. The pres-
ence of an additional AnxD with ADHD and BD further 
complicates matters, as dual-action monoamine reuptake 
inhibitors also risk precipitating a (hypo)manic episode, 
although again this would not be the case for psychologi-
cal treatments such as CBT (Goodwin et al. 2016).
Participants with BDII were significantly more likely 
on average to exhibit higher GAF scores at follow-up 
than participants with BDI. This is in line with previous 
findings showing higher GAF scores in BDII patients 
compared to BDI patients, despite similar illness dura-
tion, family history, previous suicide attempts, and over-
all psychiatric comorbidity (Dell’Osso et al. 2017b). This 
also indirectly supports the notion that psychotic symp-
toms that are particularly prevalent in BDI patients, may 
contribute to the lower GAF scores seen in this group 
(Dell’Osso et  al. 2017a). This finding is also in line with 
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the core criteria for mania as set out in DSM 5, that the 
mood episode impairs social or occupational function-
ing. AAO did not significantly influence the mean GAF 
at follow-up. As discussed previously, there is still sparse 
literature on the effects of earlier AAO on psychosocial 
functioning and their conclusions are varied (Martinez-
Aran et al. 2007; Perlis et al. 2009). It is important to note 
that this study used age at first (hypo)manic symptoms or 
depressive symptoms with dysfunction to define AAO.
Participants in the highest income class were signifi-
cantly more likely to yield better outcomes than those in 
the lowest income class. Numerous studies have shown 
that low socioeconomic status (SES) has significant det-
rimental impacts on mental health at a population level 
(Lorant et  al. 2003). However, there is little evidence 
regarding the effects of SES on psychosocial function-
ing in BD. One study found no association between edu-
cation levels and functional outcome (Schoeyen et  al. 
2011), although the outcome was ‘disability pension’; a 
fairly crude measure of psychosocial functioning.
The confounding effect observed between explanatory 
variables may be an important reason as to why individ-
ual assessment of the effects of comorbidities appeared 
to be spurious. Nevertheless, when we assess the indi-
vidual effects in conjunction with the interaction term 
we are able to ascertain the overall effect of mental health 
comorbidities on psychosocial outcomes. As our results 
indicate, those with multiple comorbidities (AnxD and 
ADHD) experience significantly reduced psychosocial 
function at follow-up.
The present study is not without limitation. First, while 
it is important that researchers use standardised scor-
ing instruments in order to reduce bias and increase the 
replicability of their findings, the GAF has several limi-
tations. Indeed, it has been suggested that it lacks the 
sensitivity to assess longitudinal change in an individual 
patient (Soderberg et  al. 2005). Moreover, the GAF is 
global measure, and as such fails to capture the contri-
butions of each specific dimension of psychosocial func-
tioning to overall dysfunction. The GAF also specifically 
excludes functional impairment due to “physical or envi-
ronmental limitations”, yet it is difficult to see how raters 
can distinguish aetiologically between physical or envi-
ronmental and psychosocial factors.
A second critical limitation to this study is that it 
did not control for mood state. The possible impact of 
mood state on the present findings is two-fold. Firstly, 
depressive symptoms, even more than manic, are 
strong predictors of poor psychosocial functioning 
(Morriss et al. 2013). However, in the present study, it 
is not possible to replicate this relationship. Secondly, 
it has been shown that the incidence rates of comor-
bidities are sensitive to mood state, when assessed 
cross-sectionally (Post et  al. 2018) as in the present 
study. It is also important to note that this study did 
not include medical comorbidities. These certainly play 
a significant role in psychosocial dysfunction but were 
beyond the scope of the current paper.
A third critical limitation is that the comorbid condi-
tions were characterised by the presence of a lifetime 
diagnosis, and whether patients continued to manifest 
these difficulties consistently over their lifetime is not 
known. This limitation would be of particular impor-
tance for ADHD, as a substantial group of patients may 
have the comorbidity in childhood and/or adolescence, 
but no longer in adulthood. Similarly, severity of each 
of the comorbid problems was not assessed. Any anx-
iety-specific disorder was considered for inclusion in 
the category, and how individual anxiety disorders or 
their combination may have affected the relationship to 
function cannot be determined in this study. In addi-
tion, while the incidence of comorbidities in this study 
population where similar to those reported in the lit-
erature, the fact that the population was drawn largely 
from academic tertiary care facilities may limit the 
generalizability of the results and conclusions to other 
populations.
It is also important to challenge some of the assump-
tions that may be drawn from this paper, including the 
idea of a unidirectional relationship between the signifi-
cant predictors and psychosocial dysfunction. As this 
study was conducted in adults, with data on predictors 
collected retrospectively, the relationships inferred are 
not conclusive. Future work should aim to clarify these 
findings using prospective studies starting in childhood 
to determine differences between those who do and do 
not go on to develop BD. This will help to inform the 
development of interventions aimed specifically at psy-
chosocial dysfunction.
Conclusion
In summary, this project has demonstrated the negative 
impact of comorbid AnxD and ADHD on psychosocial 
functioning in BD. Both inpatient and population stud-
ies have demonstrated the alarmingly high prevalence of 
comorbid disorders in BD, however current guidelines 
offer little help to clinicians when managing these disor-
ders. Our findings suggest a unique interaction between 
AnxD and ADHD in BD, which will need further research 
to both replicate and explore this relationship and ascer-
tain optimal therapeutic interventions. Resolution of 
clinical symptoms in BD is rarely followed by recovery 
of psychosocial functioning, and this study has added 
insights into the role of AnxD and ADHD comorbid dis-
orders in impairing global psychosocial functioning.
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